Navigation Links
Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
Date:3/17/2008

008. Please dial 416-695-5800 or 800-408-3053 and enter code 3255778 followed by the number sign to access the replay.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C, and a pre-clinical program directed at improving cardiovascular function.

Vernakalant (iv) is the intravenous formulation of an investigational drug being evaluated for the acute conversion of atrial fibrillation. Positive top-line results from two pivotal Phase 3 trials for vernakalant (iv), called ACT 1 and ACT 3, were released in December 2004 and September 2005. Cardiome's co-development partner Astellas Pharma US, Inc. submitted a New Drug Application for vernakalant (iv) in December 2006. Positive top-line results from an additional Phase 3 study evaluating patients with post-operative atrial arrhythmia, called ACT 2, were released in June 2007. An open-label safety study evaluating recent-onset AF patients, called ACT 4, has completed.

Vernakalant (oral) is being investigated as a chronic-use oral drug for the maintenance of normal heart rhythm following termination of AF. Cardiome announced positive results from a Phase 2a pilot study for vernakalant (oral) in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.

In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.

Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQ National Market (CRME).

Forward-Looking Statement Disclaimer

Certain
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Cardiome And Astellas Announce Regulatory Update
2. Cardiome to Hold Investor Update Call
3. Cardiome Updates Guidance
4. Cardiome Initiates Phase 1 Study for GED-aPC
5. Cardiome To Release Third Quarter Results
6. Cardiome to Present at CIBC Conference
7. Cardiome to Present at ThinkEquity Conference
8. Cardiome to Present at Bear Stearns Conference
9. Weight Watchers Announces Election of Kim Roy to Board of Directors
10. MedQuist Announces Entry Into Settlement Term Sheet Resolving South Broward Litigation
11. Exelixis Announces March 19 Webcast of Presentation at the Lehman Brothers Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... mental health and substance use problems in adolescents ... the consequences of cyberbullying and also be beneficial ... Elgar, Ph.D., of McGill University, Montreal, Canada, and ... has experienced recent online bullying and cyberbullying, like ... health problems in teens as well as the ...
(Date:9/1/2014)... shows on TV may be bad for your waistline, a ... while watching action films and programs than something less exciting, ... if you,re watching an action movie while snacking your mouth ... the Cornell Food and Brand Lab, said in a university ... is, the more you will eat." The study included ...
(Date:9/1/2014)... More than 200 Lipitor lawsuit ( http://www.thelipitorlawsuit.com/ ... that continues to progress in the U.S. District Court, ... , A federal Case List published on August 15th ... medication by plaintiffs who developed Type 2 diabetes allegedly ... failed to adequately warn patients and their doctors about ...
(Date:9/1/2014)... Barcelona, Spain Monday 1 September 2014: Daily fruit ... up to 40%, according to research presented at ESC ... The findings from the seven year follow-up study of ... found that the more fruit people ate, the more ... "CVD, including ischaemic heart disease (IHD) and stroke, is ...
(Date:9/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... MARKETS , the global market for blood-brain barrier (BBB) ... to reach $38.7 million in 2014. This is anticipated ... is equivalent to 64.9% compound annual growth rate (CAGR) ... is forecasted to grow at a CAGR of 63.8%. ...
Breaking Medicine News(10 mins):Health News:Family dinners good for teens' mental health, could protect from cyberbullying 2Health News:Family dinners good for teens' mental health, could protect from cyberbullying 3Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3
... share most of their genes, including 70 percent of ... remarkable evolutionary conservation, researchers at the Salk Institute for ... model for an innovative study of gliomas, the most ... disease but we still know very little about the ...
... non-profit Hospice By The Bay, a regional resource ... trainings in end-of-life care at no charge to ... Sonoma counties starting in March. CEUs are available. ... care are held in Larkspur. For the schedule ...
... Annual Thank Your Vet for a Healthy Pet Contest(R), ... Nutrition, Inc. and BowTie, Inc.DENVER, Feb. 12 Californian ... S. Boltz of Los Altos, Calif., as an absolute ... most knowledgeable, dedicated, passionate veterinarians she has ever encountered. ...
... 12 Charleston Laboratories, Inc, an,emerging specialty pharmaceutical ... in opioid pharmaceuticals, announced preliminary,findings from its development ... which will be used in Charleston,s clinical trials. ... study was designed to test the feasibility and,reliability ...
... Union Springs Pharmaceuticals, LLC,today announces the unveiling ... that offers a virtually impenetrable barrier,against airborne viruses ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090212/CLTH073 ) , ... ViralClyns P95 respirator has shown,to be 100 times ...
... EL SEGUNDO, Calif., Feb. 12 DaVita Inc., ... diagnosed with chronic,kidney disease (CKD) and kidney failure, ... Rate (GFR) Calculator for the Apple iPhone and,iPod ... specific versions for,English, French, Italian, Spanish and German, ...
Cached Medicine News:Health News:Fruit flies soar as lab model, drug screen for the deadliest of human brain cancers 2Health News:Fruit flies soar as lab model, drug screen for the deadliest of human brain cancers 3Health News:Hospice By The Bay Offers Health Care Professionals Free Training in End-of-Life Care 2Health News:Hospice By The Bay Offers Health Care Professionals Free Training in End-of-Life Care 3Health News:California Veterinarian Wins America's Best Vet Honor; Four Regional Winners Also Named 2Health News:California Veterinarian Wins America's Best Vet Honor; Four Regional Winners Also Named 3Health News:Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire 2Health News:Union Springs Pharmaceuticals Introduces New, More Effective Respirator 2Health News:DaVita Launches Kidney Calculator for iPhone and iPod Touch 2Health News:DaVita Launches Kidney Calculator for iPhone and iPod Touch 3
(Date:8/29/2014)... , Aug. 29, 2014   Vittamed Corporation , a ... announced today that T. (Teo) Forcht Dagi , ... company,s Board of Directors. " Teo Forcht ... in neurosurgery, medical innovation and venture capital," said Remis ... delighted to add his clinical, strategic, and entrepreneurial expertise to ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
(Date:8/29/2014)... August 29, 2014 Pixcelldata, the ... software has announced a major new deal with Dutch ... renowned pathology expert, Dr. Marius Nap . ... 26th European Congress of Pathology which is taking placing ... Arena, London where Pixcelldata will ...
Breaking Medicine Technology:Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2
... April 14, 2011 Reportlinker.com announces that a new ... Neuropathy Therapy Area Pipeline Report ... Area Pipeline Report contains detailed information on the neuropathy ... status of neuropathy drugs by company and by stage ...
... 14, 2011 Reportlinker.com announces that a new ... Juvenile Rheumatoid Arthritis (JRA) Therapeutics ... http://www.reportlinker.com/p0479828/Juvenile-Rheumatoid-Arthritis-JRA-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html ... and Market Forecasts to 2017 ...
Cached Medicine Technology:Reportlinker Adds Neuropathy Therapy Area Pipeline Report 2Reportlinker Adds Neuropathy Therapy Area Pipeline Report 3Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8
... Comfy™ Knee Orthosis Custom-fitted ... knee contractures. Goniometer version ... No exposed metal contacts ... and laundry bag. One ...
... The Pediatric Knee/Elbow Cryo/Cuff is specifically designed ... It combines the therapeutic benefits of controlled compression ... minimize pain. Due to the unique design of ... both the knee and elbow of the patient. ...
... Cryo/Cuff line, the Knee Cryo/Cuff SC is ... with water and ice eliminating the need ... amount of compression, a hand bulb is ... cuff remains cold for about one hour.,The ...
... following shoulder fusion, dislocation, reconstruction or ... the shoulder to be positioned in ... brachial plexus injury this orthosis can ... during the healing process and can ...
Medicine Products: